StockData

Drugs Made In America Acquisition Corp. (DMAA) shareholders

DMAANasdaqBlank ChecksFiscal year ends December 31Also trades as DMAAR, DMAAU
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$10.90+0.00 (0.00%)

Close on Nov 13, 2026Market cap $264.62MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
14M
Shares held, 13F filers
Institutional holders
23
1 new, 17 sold out
Net institutional buying
-9M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Drugs Made In America Acquisition LLC
Joint filing with Lynn Stockwell (12.50%)
4,188,78012.50%13D (active)Feb 18, 2025
Karpus Management, Inc.2,507,81710.33%13G (passive) amendmentJun 30, 2026
Mizuho Financial Group, Inc.2,058,6058.50%13G (passive) amendmentJun 30, 2026
Polar Asset Management Partners Inc.1,900,0005.70%13G (passive)Mar 31, 2025
Glazer Capital, LLC
Joint filing with Paul J. Glazer (5.44%)
1,822,9525.44%13G (passive)Mar 31, 2025
Feis Equities LLC
Joint filing with Lawrence M. Feis (5.08%)
1,232,7755.08%13G (passive)Jun 18, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of DMAAValueChange% of portfolio
Mizuho Securities USA LLC4,069,605–$42.83M+2,069,6050.41%
Karpus Management, Inc.2,507,817–$26.71M−22,7000.77%
Polar Asset Management Partners Inc.1,146,000–$12.20M−454,0000.20%
Glazer Capital, LLC999,899–$10.65M−678,5070.26%
Wolverine Asset Management LLC832,093–$8.86M−721,6150.08%
Highbridge Capital Management LLC809,054–$8.62M−514,2970.21%
First Trust Capital Management L.P.786,459–$8.38M−1,456,0410.49%
Heights Capital Management, Inc648,083–$6.90M−1,9171.59%
Westchester Capital Management, LLC581,790–$6.20M−1,087,2100.30%
Clear Street Group Inc.382,440–$1.65M+28,3920.00%
Aristeia Capital LLC350,000–$3.73M−531,7160.05%
Sona Asset Management (US) LLC162,795–$1.73M–0.04%
RLH Capital LLC115,606–$1.23M−200,9450.59%
Logan Stone Capital, LLC109,959–$1.17MNew0.25%
Toronto Dominion Bank100,000–$1.07M−103,8380.00%
Meteora Capital, LLC97,837–$1.04M−282,4620.09%
Quarry LP65,551–$698.12K−201,0000.06%
Geode Capital Management, LLC62,273–$663.21K–0.00%
JPMorgan Chase & Co49,891–$531.34K+100.00%
Dakota Wealth Management36,400–$387.66K–0.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares heldNew / addedReduced / closedShares boughtShares sold
Q2 20262314M1 / 315 / 172M11M
Q1 20263923M6 / 77 / 63M3M
Q4 20253923M4 / 117 / 12M1M
Q3 20253722M11 / 69 / 53M1M
Q2 20253221M11 / 76 / 25M3M
Q1 20252420M24 / 00 / 020M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

2 funds held DMAA in Q2 2026, 0% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of DMAAValue% of fundAs of
First Trust Merger Arbitrage Fund675,366–$7.19M0.44%Jun 30, 2026
First Trust Multi-Strategy Fund105,083–$1.12M0.08%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Lynn StockwellCEO and Exe. Chair of Board, Director, 10% owner4,188,780Feb 18, 2025
Glenn C. WormanCFO100,000Feb 3, 2025
Catherine DoDirector100,000Feb 3, 2025
Myron W. ShulganDirector100,000Feb 3, 2025
Sridhar G. PrasadDirector100,000Feb 3, 2025
Made In America Acquisition LLC Drugs10% owner4,188,780Feb 18, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Lynn Stockwell
CEO and Exe. Chair of Board, Director, 10% owner
Feb 18, 2025Buy+30,000––4,188,780
Made In America Acquisition LLC Drugs
10% owner
Feb 18, 2025Buy+30,000––4,188,780
Lynn Stockwell
CEO and Executive COB, Director, 10% owner
Jan 29, 2025Buy+400,000––10,257
Lynn Stockwell
CEO and Executive COB, Director, 10% owner
Jan 29, 2025Other−400,000––9,857,143
Lynn Stockwell
CEO and Executive COB, Director, 10% owner
Jan 29, 2025Sale−5,698,363––4,158,780
Made In America Acquisition LLC Drugs
10% owner
Jan 29, 2025Other−400,000––9,857,143
Made In America Acquisition LLC Drugs
10% owner
Jan 29, 2025Sale−5,698,363––4,158,780
Made In America Acquisition LLC Drugs
10% owner
Jan 29, 2025Buy+400,000––10,257,143
Sridhar G. Prasad
Director
Jan 29, 2025Other+100,000––100,000
Myron W. Shulgan
Director
Jan 29, 2025Other+100,000––100,000
Catherine Do
Director
Jan 29, 2025Other+100,000––100,000
Glenn C. Worman
CFO
Jan 29, 2025Other+100,000––100,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
5.0
At 0M shares a day
Change since last report
-4.0%
From 0M shares
Short volume, 20 days
16.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Drugs Made In America Acquisition's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,239 shares on Oct 14, 2026 over the last 90 days.

See a number that looks wrong?